Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses
Craig W Berridge1, David M Devilbiss, Matthew E Andrzejewski
1Psychology Department, University of Wisconsin, Madison, WI 53706, USA. Berridge@wisc.edu
Biological Psychiatry
|June 30, 2006
Summary
Low-dose methylphenidate (MPH) enhances dopamine and norepinephrine in the prefrontal cortex (PFC), improving attention and working memory in ADHD treatment. These effects are specific to the PFC, unlike other brain regions.
Area of Science:
- Neuroscience
- Pharmacology
- Cognitive Science
Background:
- Attention-deficit/hyperactivity disorder (ADHD) is often treated with psychostimulants like methylphenidate (MPH).
- The neural mechanisms of MPH's cognitive effects, particularly in the prefrontal cortex (PFC), are not well understood.
- Dopamine (DA) and norepinephrine (NE) are key neurotransmitters modulating PFC function and cognition.
Purpose of the Study:
- To investigate the effects of low-dose MPH on dopamine (DA) and norepinephrine (NE) neurotransmission in the rat PFC.
- To determine if MPH's actions are specific to the PFC or also affect subcortical regions.
- To correlate MPH-induced neurotransmitter changes with cognitive improvements.
Main Methods:
- In vivo microdialysis in male rats to measure DA and NE efflux.
- Administration of clinically relevant low doses of MPH (oral and intraperitoneal).
- Assessment of PFC-dependent attention and working memory.
Main Results:
- Low-dose MPH significantly increased NE and DA efflux specifically within the PFC.
- These increases occurred at doses that improved cognitive function without causing locomotor activation.
- MPH had minimal impact on NE and DA efflux in subcortical areas outside the PFC.
Conclusions:
- The therapeutic effects of low-dose MPH in ADHD may stem from preferential activation of catecholamine neurotransmission in the PFC.
- This PFC-specific action highlights the critical role of this brain region in MPH's cognitive benefits.
- Findings provide insight into the neurobiological basis of psychostimulant action in ADHD.
More Related Videos
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
07:56A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...